This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Visco, V. Articles by Muraro, R. Search for Related Content PubMed PubMed Citation Articles by Visco, V. Articles by Muraro, R.

(American Journal of Pathology. 2000;156:1417-1424.)
© 2000 American Society for Investigative Pathology

Regular Articles

ErbB2 Immune Response in Breast Cancer Patients with Soluble Receptor Ectodomain

Vincenzo Visco^*§, Roberto Bei^*§, Enrica Moriconi^*, Walter Gianni, Matthias H. Kraus and Raffaella Muraro^§

From the Department of Experimental Medicine and Pathology^*
and the Geriatric Oncology Unit,
University "La Sapienza", Rome; the Department of Experimental Oncology,
European Institute of Oncology, Milan; and the Department of Oncology and Neurosciences,^§
University "G. D’Annunzio", Chieti, Italy

Investigation of ErbB2 immunity in human breast cancer employing recombinant expression sources in immunoblot analysis revealed ErbB2-specific antibodies of the IgG isotype in sera of 14 of 71 cancer patients and 1 of 31 normal donors. Reactivity was confirmed on ErbB2-specific immunoprecipitates. Independent evidence of existing ErbB2 immunity was obtained after in vitro transformation of peripheral blood leukocytes from six positive patients. Furthermore, in vitro immortalization of B-lymphocytes unmasked existent ErbB2 immunity in 1 of 8 patients negative for ErbB2 serum antibodies. Determining shed ErbB2 extracellular domain as an indirect measure of tumor burden in ErbB2-positive malignancy, elevated serum levels were observed in 16 of 71 breast cancer and 1 of 31 normal donor sera. Strikingly, existing ErbB2 immunity correlated significantly with elevated shed ErbB2 ectodomain among the patients analyzed. Incidence of both ErbB2 immunity and elevated ErbB2 extracellular domain increased with a progressed disease stage and was significantly associated with metastatic breast cancer. These observations implicate soluble ErbB2 amounts in vivo in the development of ErbB2 immunity in breast cancer. They further project serum analysis of ErbB2 immunity and soluble ectodomain as potential markers of disease progression in ErbB2-positive malignancy.

This article has been cited by other articles:

				M. Robin, J. Andreu-Gallien, M.-H. Schlageter, D. Bengoufa, I. Guillemot, K. Pokorna, C. Robert, J. Larghero, P. Rousselot, E. Raffoux, et al. Frequent antibody production against RAR{alpha} in both APL mice and patients Blood, September 15, 2006; 108(6): 1972 - 1974. [Abstract] [Full Text] [PDF]

				C. Streckfus and L. Bigler The Use of Soluble, Salivary c-erbB-2 for the Detection and Post-operative Follow-up of Breast Cancer in Women: The Results of a Five-year Translational Research Study Adv. Dent. Res., June 1, 2005; 18(1): 17 - 24. [Full Text] [PDF]

				W. P. Carney, R. Neumann, A. Lipton, K. Leitzel, S. Ali, and C. P. Price Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer Clin. Chem., October 1, 2003; 49(10): 1579 - 1598. [Abstract] [Full Text] [PDF]

				D. Carter, D. C. Dillon, L. D. Reynolds, M. W. Retter, G. Fanger, D. A. Molesh, P. R. Sleath, P. D. McNeill, T. S. Vedvick, S. G. Reed, et al. Serum Antibodies to Lipophilin B Detected in Late Stage Breast Cancer Patients Clin. Cancer Res., February 1, 2003; 9(2): 749 - 754. [Abstract] [Full Text] [PDF]

				M. P. Piechocki, S. A. Pilon, and W.-Z. Wei Complementary Antitumor Immunity Induced by Plasmid DNA Encoding Secreted and Cytoplasmic Human ErbB-2 J. Immunol., September 15, 2001; 167(6): 3367 - 3374. [Abstract] [Full Text] [PDF]